Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,837 | 404 | 2,367 |
| Samples | 971 | 203 | 751 |
| Peptides | 803 | 180 | 624 |
Function
CIC · Capicua transcriptional repressor
The protein encoded by this gene is an ortholog of the Drosophila melanogaster capicua gene, and is a member of the high mobility group (HMG)-box superfamily of transcriptional repressors. This protein contains a conserved HMG domain that is involved in DNA binding and nuclear localization, and a conserved C-terminus. Studies suggest that the N-terminal region of this protein interacts with Atxn1 (GeneID:6310), to form a transcription repressor complex, and in vitro studies suggest that polyglutamine-expansion of ATXN1 may alter the repressor activity of this complex. Mutations in this gene have been associated with olidogdendrogliomas (PMID:21817013). In addition, translocation events resulting in gene fusions of this gene with both DUX4 (GeneID:100288687) and FOXO4 (GeneID:4303) have been associated with round cell sarcomas. There are multiple pseudogenes of this gene found on chromosomes 1, 4, 6, 7, 16, 20, and the Y chromosome. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2015].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000572681 | I3L2J0* | 924 | 663 |
| ENST00000575354 | Q96RK0-2 | 874 | 621 |
| ENST00000160740 | A0A0A0MQR4* | 872 | 619 |
| ENST00000681038 | Q96RK0 | 167 | 145 |
Gene Properties
Recurrent Mutations
All 621 amino-acid changes on canonical ENST00000575354 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CIC · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CIC – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Chordoma | 3/7 43% | 0/13 0% |
| Endometrial Carcinoma | 18/42 43% | 38/612 6% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Rhabdomyosarcoma | 3/33 9% | 10/171 6% |
| Melanoma | 12/210 6% | 104/1899 5% |
| Bladder Carcinoma | 2/58 3% | 45/956 5% |
| Glioma | 1/52 2% | 98/2127 5% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Colorectal Carcinoma | 24/143 17% | 96/3239 3% |
| Cervical Carcinoma | 0/35 0% | 15/422 4% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Gastric Carcinoma | 7/74 9% | 50/1809 3% |
| Non-Small Cell Lung Carcinoma | 22/304 7% | 26/1390 2% |
| Unknown | 0/10 0% | 1/29 3% |
| Other Solid Cancers | 5/94 5% | 31/1515 2% |
| Hodgkins Lymphoma | 0/16 0% | 3/122 2% |
| Plasma Cell Myeloma | 6/44 14% | 1/305 0% |
| Ovarian Carcinoma | 12/109 11% | 9/998 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 25/1592 2% |
| Head and Neck Carcinoma | 3/85 4% | 23/1574 1% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
| Neuroendocrine Tumour | 8/154 5% | 3/577 1% |
| Osteosarcoma | 2/45 4% | 1/166 1% |
| Biliary Tract Carcinoma | 2/54 4% | 12/950 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 12/810 1% |
| Esophageal Squamous Cell Carcinoma | 5/51 10% | 30/2550 1% |
| Ewings Sarcoma | 3/63 5% | 1/262 0% |
Mutation Distribution
Where CIC is mutated · all tissues, split by cell line vs tissue
How many mutations in CIC were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,837 mutations in CIC
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|